Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Perl

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
American Journal of Hematology|August 19, 2007
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell supportDan T Vogl, Stephen V Liu, Elise A Chong, et al.
European Journal of Haematology|December 27, 2024
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based RegimenMargaret Rowe, Daria Babushok, Martin Carroll, et al.
Cancer Discovery|April 8, 2015
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397Catherine C Smith, Chao Zhang, Kimberly C Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2024
Menin Inhibition With Revumenib for <i>KMT2A</i>-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, et al.
Blood|January 29, 2011
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseMark Levis, Farhad Ravandi, Eunice S Wang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyMartin S Tallman, Eunice S Wang, Jessica K Altman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2023
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in OncologyDaniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026Daniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Blood|November 18, 2022
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of needNaveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
American Journal of Hematology|August 19, 2007
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell supportDan T Vogl, Stephen V Liu, Elise A Chong, et al.
European Journal of Haematology|December 27, 2024
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based RegimenMargaret Rowe, Daria Babushok, Martin Carroll, et al.
Cancer Discovery|April 8, 2015
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397Catherine C Smith, Chao Zhang, Kimberly C Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2024
Menin Inhibition With Revumenib for <i>KMT2A</i>-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, et al.
Blood|January 29, 2011
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseMark Levis, Farhad Ravandi, Eunice S Wang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyMartin S Tallman, Eunice S Wang, Jessica K Altman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2023
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in OncologyDaniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026Daniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Blood|November 18, 2022
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of needNaveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, et al.
Pageof 3